Background: Meaningful patient engagement (PE) in medicines development and
| BACKG ROU N D
There is a growing consensus across stakeholder groups of the importance of patient engagement (PE) in medicines development, and during the life cycle of a product ("medicines life cycle").
There are an increasing number of efforts to achieve this. [1] [2] [3] [4] [5] [6] in the research and development setting especially has received much focus with the development of frameworks or guidance. [7] [8] [9] [10] [11] [12] [13] There are also guidance or frameworks at other milestones such as in health technology appraisal, benefit-risk assessment [14] [15] [16] [17] and in value determination. 18 The issue of definition and terminology of PE and patient centricity has also highlighted the need for a common understanding to facilitate multistakeholder teamwork. [19] [20] [21] [22] [23] Crucially, there is a need for a practical PE model that
can be assessed to demonstrate the value of PE, in terms that each stakeholder group recognizes, to encourage acceptance and implementation. 11, [24] [25] [26] [27] A recurrent theme across all these examples is collaboration to reach the common goal. This requires core elements or principles to be agreed across groups, including recognition and alignment of the A scope-defining study by Gallivan et al 23 highlighted that a "lack of consensus and understanding about terminology, the goals and expectations and roles and responsibilities of stakeholders are major barriers to achieving meaningful and successful patient engagement.
These differences in interpretation and expectation could present as barriers if not anticipated in the planning process." More recently,
Bellows et al 28 explored roles, responsibilities and expectations in PE across 3 stakeholder groups described as patients, providers and leaders. The 28 participants of the Bellows' study agreed on the importance of "clearly identifying goals, along with their roles and responsibilities."
Thus, understanding and alignment of stakeholder expectations is a critical early step in PE. This report describes the findings of a qualitative survey-based study of stakeholder expectations.
| S TUDY DE S I G N AND PRO CE SS
The study was designed to explore 4 key themes from the perspec- 
| Project design and pilot
A Stakeholder Expectations Working Group (SEWG) was established to lead the project and undertake a critical review of survey findings and outputs, and was composed of one health technol- were conducted and feedback used to refine interview questions and approach.
| Identification and categorization of interviewees
Stakeholders were grouped into 7 main categories: patients/patient representatives (termed "patients"); health-care professionals (HCPs); policymakers/regulators (termed "policy"; payers/purchasers (termed "payers"); pharma/life sciences industry (termed "industry"); academic researchers (termed "researchers"); and research funders. Note, definitions of stakeholder groups such as "policy" or "payers" may vary internationally. The categories and definitions of stakeholders were adapted from Deverka et al 7 (Appendix S1). Interviewees were identified by the SEWG and MMP using Quota and Snowball techniques to achieve a broad reach across geographies, experience of PE and job role.
| RE SULTS
A total of 59 interviews were conducted (survey questions in Appendix S2). In each of the 7 stakeholder groups, there were at least 6 (range 6-13) interviewees with a median of 7 per group including patients, n = 10; HCPs, n = 7; policy, n = 8; payers, n = 6; industry, n = 13; researchers, n = 8; and research funders, n = 7.
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| Demographics

| Geographical location
The target of one-third, respectively, of all interviewees to be from different geographical regions was mostly achieved within stakeholder groups (Figure 2 ).
| Level of experience in patient engagement
Participant's experience of PE was categorized as Experienced, Some Experience and No Experience based on the interviewees own perception. Good representation was achieved across all groups:
the level of experience varied between stakeholder groups, and no stakeholder group represented just one single level of experience (Appendix S3). interviewees cared less about terminology and more about function.
| Seniority within the organization
Each term (engagement, involvement, participation, activation, consultation) potentially has different nuances or interpretations. There may be cultural and geographical differences, as well as language barriers in the interpretation of the terms "engagement" and "involvement." A researcher interviewee noted that "…'engagement' in some languages may mean there is a fee for service."
| Views
"How important is patient engagement to your own stakeholder group now and how important should it be?" (44 answered) Overall, interviewees thought that PE should be more important than it is now and that their stakeholder group is not doing enough to address the needs of patients. The importance of PE to all groups was assessed in terms of its current level of importance and how important it should be in the future (on a scale of 1-10, with 1 being lowest and 10 highest level of importance). The current importance scored an average of 4.8, however when asked to assess what it should be this rose to 8.8 ( Figure 3 ). Interviewees recognized that PE is a key aspect to drug development, but the degree to which they were willing and able to accept an active role in PE differed. In addition, there were other agenda items such as cost and clinical effectiveness (payers/policy), medical education and scientific discussion (policy/industry), and the number of people whose quality of life can be improved (policy) that scored as more important than PE in certain stakeholder groups.
"What are your thoughts on patient engagement in medicines development in the industry right now?" (55 answered) There was an impression that there is an effort within industry to involve patients, but it is not being done well enough and more could be done.
Stakeholders were aware that patients are involved at clinical trial stage; they perceived a lack of PE at earlier stages of the drug development process, for example: A consistent theme was the need for a more systematic and structured process along with guidance. This is captured in statements from different stakeholder groups such as: 
| Goals
| Responsibility
"Do stakeholders have the same responsibility for patient engagement?" (48 answered). Fewer than half of interviewee votes (21 votes; 41%) supported the view that all stakeholders had equal responsibility. One-fifth of votes (10; 21%) were for stakeholders having "unequal responsibility," but with interviewees not being able to specify which stakeholder group should be most responsible and take the lead on PE. Where lead stakeholders were specified, industry (7 votes; 14%) and researchers (5 votes; 10%) were the most commonly cited (Figure 4 Although industry and researchers were thought by all other stakeholders to have more responsibility in PE-neither group believed they have greater responsibility.
| Stakeholder expectations matrix
Stakeholders' views of relationships, roles, goals and responsibilities were analysed together (using grounded theory analysis 
| Next steps in terms of priorities and needs
| Priorities
"What are the priority areas for your stakeholder group? And is there anything you think other groups should be focussing on?" (44 answered). Responses are summarized in Table 2 .
Interviewee responses to priorities could be broadly grouped into 4 key themes: vision, values, strategy and execution. While "vision" was generally aligned, stakeholders' views became more disparate as PE moved along the continuum towards execution.
There was agreement and shared vision that having patients involved should be a priority, and there needs to be greater collaboration with all stakeholders. There were some discrepancies in the value of, or the perception of the value others place on, having patients involved in medicines development as some stakeholder groups have their own requirements which take precedence.
There was a lack of clarity on a strategy for PE, and most stakeholders were uncertain about how to optimize, execute or implement PE in the development of medicines. There was consensus that a structured framework for PE across the entire medicines life cycle, guidelines, good practice examples and demonstration of tangible value for PE was needed to assist with practical execution, for example: There were geographical differences in priorities: generally, interviewees from the USA, Australia and parts of Europe indicated PE in medicines development as a priority; however, those from countries in other parts of the world and some European countries did not place similar importance on this.
| Needs
Are there any skill/capability or knowledge areas that you would 
| DISCUSS ION/CON CLUS ION
We have surveyed a wide range of stakeholders in a qualitative study to identify common themes and perspectives amongst and within stakeholders. 28 Our findings confirm the common understanding of the priority of PE but also show where there is less alignment or lack of clarity of roles and expectations. They highlight 3 important this is a prevailing view, it will need to be addressed because there is increasing emphasis on obtaining patient input directly from the patient rather than via a physician "vector." Consequently, it is important that HCPs take part in the dialogue and share their experience and insight.
F I G U R E 5 Stakeholder expectations matrix
Our findings suggest that "leadership" in PE must come from different sources and that collaborative leadership across different organizations is required. For this to happen, divergent expectations will need to be aligned. Collaboration also relies on relationships and trust, and our findings indicate a need to forge stronger relationships. There must be trust that PE efforts are genuine and not tokenistic. 30, 31 Given the call for a framework and guidance, the implication is that stakeholders have evolved from a position of "shall we?" to "we shall…. but how?" Collaborative leadership will also be required to cocreate a framework and methodology for PE In conclusion, this qualitative multistakeholder survey builds on insights from others on the need to align expectations in PE. 11, 23, 28, 32, 33 Importantly, it highlights that there is no "leader"; no stakeholder group has a clear view on how to meaningfully engage with patients; there are educational gaps; and a structure and guidance for PE is urgently required. Given the diversity of stakeholders in PE, the potential for conflict of interest, and that different stakeholders may have different drivers for and requirements from PE, there needs to be cross-stakeholder collaboration-facilitated by platforms where stakeholders can connect and work together in a non-competitive way-to address these issues. Such collaboration will only be effective when there is understanding of (and consensus on) roles, responsibilities and expectations. This is essential if we are to synergize PE efforts, have realistic and achievable goals, and prevent misunderstanding and disappointments that can hamper even the most worthwhile endeavours. We hope that the findings from this survey will inform the essential conversations between stakeholders, facilitate alignment and deliver meaningful PE in medicines development.
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